MODRASTANE
LOE Approachingtrilostane
NDAORALCAPSULE
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODRASTANE (trilostane) is an oral small-molecule steroid synthesis inhibitor approved in 1984 for adrenocortical disorders. It reduces cortisol production by inhibiting the enzyme 3β-hydroxysteroid dehydrogenase in the adrenal cortex. The drug is primarily used in veterinary medicine and has limited human indications.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; limited team size expected for legacy asset management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Trilostane for Androgen-Independent Prostate Cancer
Started Mar 2004
24 enrolled
Prostate CancerProstate Adenocarcinoma
Career Relevance
MODRASTANE offers limited career growth given zero linked job postings and approaching LOE status. Roles available are primarily in legacy product management, compliance, and generic defense rather than expansion or innovation.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.